Dynamically borrowing strength from another study through shrinkage estimation

Abstract

Meta-analytic methods may be used to combine evidence from different sources of information. Quite commonly, the normal-normal hierarchical model (NNHM) including a random-effect to account for between-study heterogeneity is utilized for such analyses. The same modeling framework may also be used to not only derive a combined estimate, but also to borrow strength for a particular study from another by deriving a shrinkage estimate. For instance, a small-scale randomized controlled trial could be supported by a non-randomized study, e.g. a clinical registry. This would be particularly attractive in the context of rare diseases. We demonstrate that a meta-analysis still makes sense in this extreme two-study setup, as illustrated using a recent trial and a clinical registry in Creutzfeld-Jakob disease. Derivation of a shrinkage estimate within a Bayesian random-effects meta-analysis may substantially improve a given estimate even based on only a single additional estimate while accounting for potential effect heterogeneity between the studies. Alternatively, inference may equivalently be motivated via a model specification that does not require a common overall mean parameter but considers the treatment effect in one study, and the difference in effects between the studies. The proposed approach is quite generally applicable to combine different types of evidence originating e.g. from meta-analyses or individual studies. An application of this more general setup is provided in immunosuppression following liver transplantation in children.

arXiv comment23 pages, 3 figures, 4 tables

References in corpus (7)

• Meta-analysis of few small studies in orphan diseases
• Meta-analysis of two studies in the presence of heterogeneity with applications in rare diseases
• Interleukin-2 receptor antagonists for pediatric liver transplant recipients: A systematic review and meta-analysis of controlled studies
• Model averaging for robust extrapolation in evidence synthesis
• Using phase II data for the analysis of phase III studies: an application in rare diseases
• Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions
• Contribution to the discussion of "When should meta-analysis avoid making hidden normality assumptions?": A Bayesian perspective

Cited by in corpus (9)

• On weakly informative prior distributions for the heterogeneity parameter in Bayesian random-effects meta-analysis
• Bounds for the weight of external data in shrinkage estimation
• How trace plots help interpret meta-analysis results
• A Tree-based Model Averaging Approach for Personalized Treatment Effect Estimation from Heterogeneous Data Sources
• A straightforward meta-analysis approach for oncology phase I dose-finding studies
• Use of Historical Individual Patient Data in Analysis of Clinical Trials
• Incorporating External Data into the Analysis of Clinical Trials via Bayesian Additive Regression Trees
• Shrinkage estimation for dose-response modeling in phase II trials with multiple schedules
• Integrate Meta-analysis into Specific Study (InMASS) for Estimating Conditional Average Treatment Effect